Funds and ETFs Janux Therapeutics, Inc.

Equities

JANX

US47103J1051

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 03:28:19 2024-05-14 pm EDT 5-day change 1st Jan Change
47.78 USD -4.41% Intraday chart for Janux Therapeutics, Inc. -22.48% +344.32%

ETFs positioned on Janux Therapeutics, Inc.

Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidate includes JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr), being investigated in a Phase I clinical trial in adult subjects with metastatic castration-resistant prostate cancer (mCRPC). JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
49.99 USD
Average target price
63.57 USD
Spread / Average Target
+27.17%
Consensus
  1. Stock Market
  2. Equities
  3. JANX Stock
  4. Funds and ETFs Janux Therapeutics, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW